Post-test

Please mark the single best answer to each question.  The questions with an asterisk are mandatory.  Please answer:

Question Title

3. AOA ID Number?
(If you do not have or know your AOA ID, please enter None or Unknown)
(Required.)

Question Title

4. Contact Information for Attendee (Required.)

Question Title

5. Primary State or Foreign Country of Practice: (Required.)

Question Title

6. Please select your profession: (Required.)

Question Title

7. I have a Registration with the DEA to prescribe controlled substances (CS) (Required.)

Question Title

8. Do you perform surgical procedures? (Required.)

Question Title

9. Please indicate the primary area of your clinical practice: (Required.)

Question Title

10. How long have you been in clinical practice? (Required.)

Question Title

11. Have you prescribed ER/LA opioids within the past year?

Question Title

12. Which comorbid condition may predict the development of chronic pain following acute pain?

Question Title

13. Pain secondary to post-herpetic neuralgia is what type of pain?

Question Title

14. Which of the following is an anticipated outcome of a patient taking a prescribed opioid medication as recommended?

Question Title

15. What is the first step in assessment of a patient’s pain who complains of burning and tingling in his lower extremities?

Question Title

16. Which of the following is the most important thing to consider in creating a pain treatment plan?

Question Title

17. According to expert guidelines, which of the following is the best sequence for establishing a pain treatment plan of care?

Question Title

18. Which side effect of opioid therapy should always prompt proactive treatment?

Question Title

19. In which of the following circumstances is the patient at greatest risk of life-threatening respiratory depression from opioid treatment?

Question Title

20. Select the correct statement regarding counseling a woman, currently on chronic opioid therapy, who is contemplating a possible pregnancy.

Question Title

21. After determining that non-opioid therapies are inadequate for a patient’s pain, which of the following are the three most important things to have in place at the beginning of a trial of opioids?

Question Title

22. While all of the following behaviors might merit investigation in a patient receiving long term opioid therapy, which would most strongly prompt your concern for a possible opioid use disorder?

Question Title

23. In transitioning an 80 y/o patient from morphine 180 mg/day to oxycodone, and accounting for incomplete cross-tolerance, which one of the following would be an appropriate initial dose? Recall that thirty (30) mg of PO morphine is approximately equianalgesic to 20 mg long-acting oxycodone; that is, the equianalgesic ratio for morphine: oxycodone is 3:2 (although some tables indicate, oxycodone is roughly twice as potent as morphine).

Question Title

24. Of the following, which is an appropriate reason for tapering and discontinuing opioid medication and not a situation that calls for further investigation and increased monitoring?

Question Title

25. What is the most important piece of information when educating patients and their families about naloxone use?

T